Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Clinical Benefit of PCSK9i in STEMI Patients
NCT05579418Phase 4Unknown
- Sponsor
- Hamad Medical Corporation
- Start
- Nov 2022
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
01
Overview
Phase 4, randomised, open-label trial of evolocumab in ST elevation myocardial infarction (STEMI) (2 arms), sponsored by Hamad Medical Corporation. Primary endpoints: Major cardiovascular events at 12 months and Safety of PCSK9i at 12 months. Status: unknown.
02
Drugs
evolocumab
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT05579418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05579418.